share_log

君實生物：海外監管公告

JUNSHI BIO: Overseas regulatory announcement.

HKEX ·  Dec 20, 2024 20:08

Summary by Moomoo AI

君實生物於2024年12月20日召開2024年第一次臨時股東大會，會議審議通過了三項重要議案。首先，公司獲准使用剩餘超募資金永久補充流動資金，該議案獲得99.75%的股東支持。其次，公司將變更註冊地址並修訂公司章程，此特別決議以99.77%的高票通過。最後，會議選舉郦仲賢先生和魯琨女士為第四屆董事會獨立非執行董事，兩人分別獲得99.45%和99.40%的支持率。緊隨股東大會後，公司召開第四屆董事會第六次會議，對董事會專門委員會成員進行了調整。郦仲賢先生被選為審計委員會委員，GANG WANG（王剛）先生和馮曉源先生被選為戰略委員會委員。調整後，審計委員會由張淳先生（主任委員）、湯毅先生和郦仲賢先生組成；戰略委員會由熊俊先生（主任委員）、鄒建軍女士、GANG WANG（王剛）先生、張淳先生和馮曉源先生組成。新任委員任期與第四屆董事會一致。
君實生物於2024年12月20日召開2024年第一次臨時股東大會，會議審議通過了三項重要議案。首先，公司獲准使用剩餘超募資金永久補充流動資金，該議案獲得99.75%的股東支持。其次，公司將變更註冊地址並修訂公司章程，此特別決議以99.77%的高票通過。最後，會議選舉郦仲賢先生和魯琨女士為第四屆董事會獨立非執行董事，兩人分別獲得99.45%和99.40%的支持率。緊隨股東大會後，公司召開第四屆董事會第六次會議，對董事會專門委員會成員進行了調整。郦仲賢先生被選為審計委員會委員，GANG WANG（王剛）先生和馮曉源先生被選為戰略委員會委員。調整後，審計委員會由張淳先生（主任委員）、湯毅先生和郦仲賢先生組成；戰略委員會由熊俊先生（主任委員）、鄒建軍女士、GANG WANG（王剛）先生、張淳先生和馮曉源先生組成。新任委員任期與第四屆董事會一致。
JUNSHI BIO held its first extraordinary Shareholder meeting of 2024 on December 20, 2024, where three important resolutions were approved. First, the company was authorized to permanently replenish working capital using the remaining overraised funds, which received 99.75% support from Shareholders. Second, the company will change its registered address and amend its articles of association, with this special resolution passing at a high rate of 99.77%. Finally, Mr. Li Zhongxian and Ms. Lu Kun were elected as independent non-executive directors of the fourth Board of Directors, receiving support rates of 99.45% and 99.40%, respectively.Following the Shareholder meeting, the company held the sixth meeting of the fourth Board of Directors, where adjustments were made to the members of the Board's specialized committees. Mr. Li Zhongxian...Show More
JUNSHI BIO held its first extraordinary Shareholder meeting of 2024 on December 20, 2024, where three important resolutions were approved. First, the company was authorized to permanently replenish working capital using the remaining overraised funds, which received 99.75% support from Shareholders. Second, the company will change its registered address and amend its articles of association, with this special resolution passing at a high rate of 99.77%. Finally, Mr. Li Zhongxian and Ms. Lu Kun were elected as independent non-executive directors of the fourth Board of Directors, receiving support rates of 99.45% and 99.40%, respectively.Following the Shareholder meeting, the company held the sixth meeting of the fourth Board of Directors, where adjustments were made to the members of the Board's specialized committees. Mr. Li Zhongxian was elected as a member of the audit committee, and Mr. GANG WANG and Mr. Feng Xiaoyuan were elected to the strategic committee. After the adjustments, the audit committee consists of Mr. Zhang Chun (chairman), Mr. Tang Yi, and Mr. Li Zhongxian; the strategic committee consists of Mr. Xiong Jun (chairman), Ms. Zou Jianjun, Mr. GANG WANG, Mr. Zhang Chun, and Mr. Feng Xiaoyuan. The term of the new members is consistent with that of the fourth Board of Directors.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    BIOCYTOGEN-B
    02315
    -- 7.790
    YUNKANG GROUP
    02325
    -- 5.800
    REMEGEN
    09995
    -- 13.060
    CSTONE PHARMA-B
    02616
    -- 2.380
    KEYMED BIO-B
    02162
    -- 30.850
    Log In for the Full List
    Discussing
    Trump 2.0 Era: What's the next opportunity in the markets?
    ▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks Show More
    Ask a strategist - Trump's first day